Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A

Affiliations

• ¹ CHU de Caen, Hematology Laboratory, Caen, France.
• ² INSERM, U1237, GIP Cyceron, Caen, France.
• ³ Normandie Université, UNI-CAEN, UFR Santé, Caen, France.
• ⁴ Service de Génétique et Biologie Moléculaires, APHP, Groupe Hospitalier Cochin Broca, Hôtel-Dieu, Site Cochin, Paris, France.
• ⁵ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
• ⁶ Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.
• ⁷ Centres de Traitement de l'Hémophilie, APHP, Le Kremlin-Bicêtre, France.
• ⁸ Centres de Traitement de l'Hémophilie, APHP, Hôpital Necker, Paris, France.
• ⁹ Pediatric Hematology Department, Cairo University Pediatric Hospital, Cairo, Egypt.
• ¹⁰ Faculty of Medicine, Ain Shams Center, University - Department of Pediatrics, Cairo, Egypt.
• ¹¹ Jehangir Clinical Development Center, Department of Hematology, Jehangir Hospital Premises, Pune, India.
• ¹² Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
• ¹³ Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
• ¹⁴ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
• ¹⁵ Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France [email protected].